Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Nov 2021
NICE does not recommend elosulfase alfa for NHS use following evaluation of new evidence
12 November 2021 - NICE has today published draft guidance for public consultation which does not recommend elosulfase alfa (also called ...
Posted by Michael Wonder on 12 Nov 2021
First in class medicine recommended for treatment of rare blood vessel inflammation
12 November 2021 - EMA has recommended granting a marketing authorisation in the European Union for Tavneos (avacopan), a first in ...
Posted by Michael Wonder on 12 Nov 2021
Progress update: post-market review of medicines for smoking cessation
12 November 2021 - In June 2021, the Drug Utilisation Sub-Committee and the Economics Sub-Committee of the PBAC considered the report ...
Posted by Michael Wonder on 11 Nov 2021
Three cancer drugs approved for NHS use in Scotland
10 November 2021 - Three new cancer drugs have been given the go-ahead by the SMC for routine use in ...
Posted by Michael Wonder on 11 Nov 2021
FDA touts success and challenges in biosimilar development
10 November 2021 - A top official from the US FDA offered a mixed assessment of the agency’s biosimilars program, noting ...
Posted by Michael Wonder on 11 Nov 2021
Health tech questions await next FDA chief
10 November 2021 - Twenty months into the pandemic, the FDA remains consumed with vital decisions on coronavirus vaccines and treatments. ...
Posted by Michael Wonder on 11 Nov 2021
Bolstering our ability to value health technology: a few less considered issues
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...
Posted by Michael Wonder on 11 Nov 2021
Inclusion in health technology assessments: the first step toward equity
10 November 2021 - Many researchers working on health technology assessments are keen to address disparities in health care. ...
Posted by Michael Wonder on 11 Nov 2021
European Council green lights new rules on health technology assessment, improving access to medicines and simplifying procedures
9 November 2021 - The Council today gave its final go-ahead for the adoption of a regulation on health technology assessment. ...
Posted by Michael Wonder on 11 Nov 2021
Average family premiums for employer-based health insurance have jumped 47% in the last decade, outpacing wage growth and inflation
11 November 2021 - You’re not imagining the growing pinch to your budget from the cost of your workplace health ...
Posted by Michael Wonder on 11 Nov 2021
Patient access to affordable cancer treatment increases with the launch of new biosimilar in Canada
9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with ...
Posted by Michael Wonder on 11 Nov 2021
US FDA accepts supplemental new drug application and grants priority review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
11 November 2021 - If approved, Jardiance would be the first clinically proven treatment for adults across the full spectrum ...
Posted by Michael Wonder on 11 Nov 2021
Valneva receives EU deal for COVID jab, and seeks apology from UK
11 November 2021 - French vaccine manufacturer, Valneva, has announced that it has won EU approval to supply up to 60 ...
Posted by Michael Wonder on 11 Nov 2021
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines
11 November 2021 - EMA’s CHMP has recommended authorising Ronapreve (casirivimab/imdevimab) and Regkirona (regdanvimab) for COVID-19. ...
Posted by Michael Wonder on 11 Nov 2021
Moderna booster progress ‘well advanced’ as regulator considers child vaccines
11 November 2021 - Moderna’s coronavirus vaccine could be approved for use as a booster within weeks and the medical ...